Cardiol Therapeutics Files 6-K, Incorporates Exhibits
Ticker: CRDL · Form: 6-K · Filed: Oct 8, 2024 · CIK: 1702123
Sentiment: neutral
Topics: filing, registration, regulatory
TL;DR
Cardiol Therapeutics filed a 6-K on Oct 8, incorporating exhibits into its F-10. Standard update.
AI Summary
Cardiol Therapeutics Inc. filed a Form 6-K on October 8, 2024, incorporating Exhibits 99.1 and 99.2 by reference into its Form F-10 registration statement (File No. 333-280713). This filing is for the month of October 2024 and pertains to its status as a foreign private issuer.
Why It Matters
This filing indicates that Cardiol Therapeutics is continuing to update its registration statement, which is a necessary step for ongoing capital raising or listing activities.
Risk Assessment
Risk Level: low — This is a routine administrative filing that incorporates previously submitted exhibits into an existing registration statement.
Key Players & Entities
- Cardiol Therapeutics Inc. (company) — Registrant
- October 8, 2024 (date) — Filing date
- Form 6-K (document) — Filing type
- Form F-10 (document) — Incorporated into
- 333-280713 (document) — Registration statement file number
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is a report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of October 2024.
What exhibits are being incorporated by reference?
Exhibits 99.1 and 99.2 to this report on Form 6-K are incorporated by reference.
Into which registration statement are these exhibits being incorporated?
The exhibits are incorporated into the Registration Statement on Form F-10 of Cardiol Therapeutics Inc. (File No. 333-280713).
What is the principal executive office address of Cardiol Therapeutics Inc.?
The principal executive office is located at 602-2265 Upper Middle Road East, Oakville, Ontario L6H 0G5, Canada.
When was this Form 6-K filed?
This Form 6-K was filed on October 8, 2024.
Filing Stats: 227 words · 1 min read · ~1 pages · Grade level 10.9 · Accepted 2024-10-08 17:10:14
Filing Documents
- tm2424074d3_6k.htm (6-K) — 11KB
- tm2424074d3_ex99-1.htm (EX-99.1) — 4KB
- tm2424074d3_ex99-2.htm (EX-99.2) — 4KB
- tm2424074d3_ex99-3.htm (EX-99.3) — 11KB
- tm2424074d3_ex99-1img001.jpg (GRAPHIC) — 4KB
- tm2424074d3_ex99-2img001.jpg (GRAPHIC) — 13KB
- tm2424074d3_ex99-2img002.jpg (GRAPHIC) — 27KB
- tm2424074d3_ex99-3img001.jpg (GRAPHIC) — 19KB
- tm2424074d3_ex99-3img002.jpg (GRAPHIC) — 2KB
- 0001104659-24-107081.txt ( ) — 120KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CARDIOL THERAPEUTICS INC. (Registrant) Date: October 8, 2024 By: /s/ Chris Waddick Name: Chris Waddick Title: Chief Financial Officer Form 6-K Exhibit Index Exhibit Number Document Description 99.1 Consent of Borden Ladner Gervais LLP, dated October 8, 2024 99.2 Consent of Stikeman Elliott LLP, dated October 8, 2024 99.3 News Release dated October 8 , 2024 – Cardiol Therapeutics Files Preliminary Prospectus Supplemental for Proposed Public Offering of Common Shares